Zafgen Announces Transition of Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
FBR Capital Remains Bullish on Zafgen (ZFGN) Following Announced Orphan Designation of Beloranib in EU
September 30, 2015 10:31 AM EDTFBR Capital reiterated an Outperform rating on Zafgen (NASDAQ: ZFGN) following announced orphan designation of beloranib in the EU for the treatment of craniopharyngioma.
Analyst Christopher James commented, "This morning, Zafgen announced that it was granted orphan designation of beloranib in the EU for... More
